Author: Anand Swaminathan

The DEVT + SKIP Trials: Does Systemic Thrombolysis Prior to Endovascular Treatment Improve Outcomes in Large Vessel Occlusion Strokes?

by Anand Swaminathan posted March 18, 2021 No Comments

Background: The publication of the MR CLEAN trial in January 2015 changed the face of ischemic stroke care. This was the first study demonstrating a benefit to endovascular treatment of a specific subset of ischemic stroke patients: those with a …

Neurology

REBEL Core Cast 51.0 – Conference Pearls

by Anand Swaminathan posted March 10, 2021 No Comments

CardiovascularInfectious Disease

REBEL Cast Ep97: The NoPAC Trial – TXA for Epistaxis?

by Anand Swaminathan posted March 6, 2021 No Comments

Background: Epistaxis is a common Emergency Department (ED) complaint with over 450,000 visits per year and a lifetime incidence of 60% (Gifford 2008, Pallin 2005). Standard anterior epistaxis treatment consists of holding pressure, use of local vasoconstrictors, topical application of …

Head, Eye, Ear, Nose, and Throat

REBEL Core Cast 50.0 – Superficial Venous Thrombosis

by Anand Swaminathan posted February 24, 2021 No Comments

Take Home Points SVT >5cm or <3 cm from the SFJ should be treated with anti-coagulation. The rate of concurrent DVT and PE in patients with SVT is 25% and 5%, respectively.

Hematology and Oncology

Does D Stand for Decrease Deterioration + Death? – The Jury is Out for Vitamin D in COVID

by Anand Swaminathan posted February 19, 2021 No Comments

Update: This article was removed from the Lancet server on February 19th, 2021 (Link) Background: Vitamin D deficiency is common amongst critically ill patients and there has been ample speculation about a possible role for supplementation (with calcifediol) in the …

Infectious Disease